.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,025,391

« Back to Dashboard

Claims for Patent: 6,025,391

Title: Enteric-coated pharmaceutical compositions of mycophenolate
Abstract:Disclosed are pharmaceutical compositions which have been modified to release pharmaceutically acceptable mycophenolate salts in the upper part of the intestinal tract and methods of treatment using the pharmaceutical compositions.
Inventor(s): Haeberlin; Barbara (Riehen, CH), Mak; Ching-Pong (Therwil, CH), Meinzer; Armin (Buggingen, DE), Vonderscher; Jacky (Riedisheim, FR)
Assignee: Novartis AG (Basel, CH)
Application Number:09/077,398
Patent Claims: 1. A pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to prevent release of the mycophenolate salt in the stomach and to release the mycophenolate salt in the upper part of the intestinal tract.

2. A pharmaceutical composition comprising an enteric coated pharmaceutically acceptable mycophenolate salt.

3. A method of immunosuppressing a subject which comprises administering a therapeutically effective amount of enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 to a subject in need of such immunosuppression, optionally with the simultaneous or separate administration of another immunosuppressant.

4. A composition containing an enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 and another immunosuppressant for simultaneous, sequential or separate administration.

5. A pharmaceutical composition according to claim 1 wherein the mycophenolate salt is a mono-sodium salt.

6. A pharmaceutical composition according to claim 2 wherein the mycophenolate salt is a mono-sodium salt.

7. A method according to claim 3 wherein the mycophenolate salt is a mono-sodium salt.

8. A method according to claim 3 wherein said another immunosuppressant is cyclosporin.

9. A pharmaceutical composition according to claim 4 wherein the mycophenolate salt is a mono-sodium salt.

10. A pharmaceutical composition according to claim 9 wherein said another immunosuppressant is cyclosporin.

11. A pharmaceutical composition according to claim 4 wherein said another immunosuppressant is cyclosporin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc